PD-1-blocking antibodies, either as monotherapy or in combination with other compounds, have been used to enhance anti-tumor immunity in several cancer types with an acceptable safety profile9–12 and together with antibodies targeting CTLA-4 have revolutionized cancer treatment13. The gene discussed is RPL17; the disease is neoplasm.